Exome Sequencing of Eight Cancer Cell Lines
Author Information
Author(s): Chang Han, Jackson Donald G. Kayne, Paul S. Ross-Macdonald, Petra B. Ryseck, Rolf-Peter Siemers, Nathan O.
Primary Institution: Bristol-Myers Squibb Company
Hypothesis
Can exome sequencing effectively identify genomic alterations in cancer cell lines?
Conclusion
Exome sequencing is a reliable and cost-effective method for identifying genomic alterations in cancer cell lines.
Supporting Evidence
- Exome sequencing identified an average of 2,779 potential novel sequence variations per cell line.
- The study showed 95% concordance with SNP Array 6.0 results.
- 19 out of 21 mutations reported in the COSMIC database were detected.
- High-level gene amplifications and homologous deletions were identified using read-depth data.
Takeaway
Scientists looked at the DNA of eight cancer cell lines to find changes that could help us understand cancer better. They found many new changes that might affect how cancer grows.
Methodology
Exome sequencing was performed using Roche Nimblegen capture and 454 sequencing technologies on DNA from eight cancer cell lines.
Potential Biases
Potential biases may arise from the unevenness in the exome capturing process and random variations in read depth.
Limitations
The study's findings may be limited by the sequencing read depth and the coverage of the exome capture array.
Participant Demographics
The study analyzed eight cancer cell lines from various tissue origins, including ovary, lung, colon, stomach, breast, prostate, and soft tissue.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website